104 related articles for article (PubMed ID: 9249875)
1. p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma.
Ollikainen H; Syrjänen S; Koskela K; Pelliniemi TT; Pulkki K
Scand J Clin Lab Invest; 1997 Jul; 57(4):281-9. PubMed ID: 9249875
[TBL] [Abstract][Full Text] [Related]
2. p53 gene mutations in multiple myeloma.
Owen RG; Davis SA; Randerson J; Rawstron AC; Davies F; Child JA; Jack AS; Morgan GJ
Mol Pathol; 1997 Feb; 50(1):18-20. PubMed ID: 9208809
[TBL] [Abstract][Full Text] [Related]
3. Rare occurrence of P53 gene mutations in multiple myeloma.
Preudhomme C; Facon T; Zandecki M; Vanrumbeke M; Laï JL; Nataf E; Loucheux-Lefebvre MH; Kerckaert JP; Fenaux P
Br J Haematol; 1992 Jul; 81(3):440-3. PubMed ID: 1390218
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
5. N-ras and p53 gene mutations are very rare events in multiple myeloma.
Yasuga Y; Hirosawa S; Yamamoto K; Tomiyama J; Nagata K; Aokia N
Int J Hematol; 1995 Aug; 62(2):91-7. PubMed ID: 8590778
[TBL] [Abstract][Full Text] [Related]
6. p53 protein accumulation and gene mutations in human glioma cell lines.
Anker L; Ohgaki H; Ludeke BI; Herrmann HD; Kleihues P; Westphal M
Int J Cancer; 1993 Dec; 55(6):982-7. PubMed ID: 8253536
[TBL] [Abstract][Full Text] [Related]
7. A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.
Yufu Y; Goto T; Choi I; Uike N; Kozuru M; Ohshima K; Taniguchi T; Motokura T; Yatabe Y; Nakamura S
Cancer; 1999 Apr; 85(8):1750-7. PubMed ID: 10223569
[TBL] [Abstract][Full Text] [Related]
8. Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial multiple myeloma pedigrees.
Willems PM; Kuypers AW; Meijerink JP; Holdrinet RS; Mensink EJ
Leukemia; 1993 Jul; 7(7):986-91. PubMed ID: 8321049
[TBL] [Abstract][Full Text] [Related]
9. Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells.
Hietanen SH; Kurvinen K; Syrjänen K; Grénman S; Carey T; McClatchey K; Syrjänen S
Am J Obstet Gynecol; 1995 Nov; 173(5):1477-82. PubMed ID: 7503188
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive system to explore p53 mutations.
Furuwatari C; Yagi A; Yamagami O; Ishikawa M; Hidaka E; Ueno I; Furihata K; Ogiso Y; Katsuyama T
Am J Clin Pathol; 1998 Sep; 110(3):368-73. PubMed ID: 9728612
[TBL] [Abstract][Full Text] [Related]
11. [Mutations of p53 gene in 41 cases of human brain gliomas].
Cui W; Kong X; Cao HL; Wang X; Gao JF; Wu RL; Wang XC
Ai Zheng; 2008 Jan; 27(1):8-11. PubMed ID: 18184456
[TBL] [Abstract][Full Text] [Related]
12. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors.
Meyers FJ; Gumerlock PH; Chi SG; Borchers H; Deitch AD; deVere White RW
Cancer; 1998 Dec; 83(12):2534-9. PubMed ID: 9874460
[TBL] [Abstract][Full Text] [Related]
13. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network.
Gumerlock PH; Chi SG; Shi XB; Voeller HJ; Jacobson JW; Gelmann EP; deVere White RW
J Natl Cancer Inst; 1997 Jan; 89(1):66-71. PubMed ID: 8978408
[TBL] [Abstract][Full Text] [Related]
14. Dissemination and tissue invasiveness in murine acute leukemia associated with acquisition of p53 mutation and loss of wild-type p53.
Hsiao M; Wu CY; Low J; Pattengale P; Yeargin J; Haas M
Mol Carcinog; 1995 Jun; 13(2):112-21. PubMed ID: 7605579
[TBL] [Abstract][Full Text] [Related]
15. p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro.
Sen S; Zhou H; Andersson BS; Cork A; Freireich EJ; Stass SA
Cancer Genet Cytogenet; 1995 Jul; 82(1):35-40. PubMed ID: 7627932
[TBL] [Abstract][Full Text] [Related]
16. p53 alterations in thymic epithelial tumours.
Weirich G; Schneider P; Fellbaum C; Brauch H; Nathrath W; Scholz M; Präuer H; Höfler H
Virchows Arch; 1997 Jul; 431(1):17-23. PubMed ID: 9247629
[TBL] [Abstract][Full Text] [Related]
17. Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer.
Provencher DM; Lounis H; Fink D; Drouin P; Mes-Masson AM
Tumour Biol; 1997; 18(3):167-74. PubMed ID: 9143413
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
[TBL] [Abstract][Full Text] [Related]
19. Identification of p53 gene mutations in breast cancers and their effects on transcriptional activation function.
Oh SJ; Jung JY; Shim SS; Im MY; Kim HD; Chung SY; Yoon JH
Mol Cells; 2000 Jun; 10(3):275-80. PubMed ID: 10901165
[TBL] [Abstract][Full Text] [Related]
20. Mutations of p53 gene in gastric carcinoma in Taiwan.
Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
